Expert opinion on priority risk groups for influenza vaccination

Expert opinion-28 Aug 2008

This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.

Programmatic management of latent tuberculosis infection in the European Union

Public health guidance-15 Oct 2018

Programmatic management of latent tuberculosis infection (LTBI) is a key component of the global tuberculosis (TB) elimination strategy. This document provides evidence-based guidance for the implementation of programmatic management of LTBI in the European Union and European Economic Area (EU/EEA).

Systematic review on the diagnosis, treatment, care and prevention of tuberculosis in prison settings

Systematic review-30 May 2017

The objective of this report is to systematically review data on the diagnosis, treatment, care and prevention of tuberculosis in prison settings, with a focus on the countries of the European Union and the European Economic Area.

Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses

Expert opinion-14 Aug 2017

This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.

Public health guidance on investigation and control of tuberculosis incidents affecting children in congregate settings

Public health guidance-13 Dec 2013

​This report aims to bring the different components of generic outbreak management and tuberculosis specific policies and guidelines together, to develop a more comprehensive package of guidance to capture the elements that are specific for TB incidents affecting children in congregate settings.

Public health guidance on chlamydia control in Europe

Public health guidance-30 Jun 2009

This document outlines the steps necessary to implement a comprehensive and effective control programme. It also offers advice on how to monitor and evaluate such programmes in order to ensure their effectiveness.

Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA - First update

Technical report-29 Apr 2020

This first update of the original document is prompted by the recent scientific developments and evolution of the coronavirus 2019 (COVID-19) pandemic and the need to include types of substances of human origin (SoHO) that were not addressed in the first version (e.g. reproductive and some non-reproductive tissues and cells).

Surveillance of COVID-19 at long-term care facilities in the EU/EEA

Technical report-19 May 2020

The high COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in EU/EEA countries poses a major challenge for disease prevention and control in such settings. Furthermore, the lack of special surveillance systems and the differences in testing strategies and capacities among countries may have led to a significant under-ascertainment and under-reporting of cases, contributing to a general underestimation of the disease burden and mortality in LTCFs.

Public health guidance on management of contacts of MDR TB and XDR TB patients

Public health guidance-20 Mar 2012

The goal of this guidance is to contribute towards preventing as many MDR TB and XDR TB cases as possible in the EU/EEA. Given that MDR TB and XDR TB is becoming more prevalent, the issue of how to manage contacts of MDR TB patients is becoming increasingly relevant. The specific aim of this document is to provide guidance on issues relevant to the management of contacts of MDR TB and XDR TB patients.

Infection prevention and control and preparedness for COVID-19 in healthcare settings - third update

Technical report-13 May 2020

This document aims to provide guidance to EU/EEA healthcare facilities and healthcare providers on infection prevention and control (IPC) measures for the management of suspected and confirmed cases of COVID-19 infection in healthcare settings, including long-term care facilities. It also offers guidance on the management of specimens at laboratories in the EU/EEA.